NCT02979301已完成不适用
Low-Dose Tamoxifen to Reduce High Background Parenchymal Uptake on Molecular Breast Imaging
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Mayo Clinic
- 入组人数
- 22
- 试验地点
- 1
- 主要终点
- Change in Background Parenchymal Uptake (BPU) on Molecular Breast Imaging (MBI)
研究概览
简要总结
The study will examine whether changes in background parenchymal uptake (BPU) on molecular breast imaging (MBI) can be induced by short-term use of low-dose tamoxifen. Women who have previously had high BPU on MBI will be recruited. Participants will take low-dose tamoxifen for a 30-day period, with post-tamoxifen MBI in order to investigate the impact of tamoxifen on BPU.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 40 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •The following are requirements for entry into the study:
- •Female, age 40 or older at the time of enrollment
- •Most recent MBI examination, performed within 3 years of enrollment, showed moderate or marked background parenchymal uptake
- •Mammogram performed within 12 months prior to enrollment that is available for comparison
- •Willing and able to return for MBI following 30 days of low-dose tamoxifen
- •If able to become pregnant
- •Negative pregnancy test within 48 hours prior to study MBI exam(s)
- •Agrees to avoid pregnancy during the study and for at least 2 months after study participation ends, by abstinence, barrier method, or nonhormonal contraception.
- •Understands and signs the consent form
排除标准
- •Subjects will be excluded if any of the following characteristics are present:
- •Evidence of suspected breast disease as defined by positive findings or recommendation for short-interval follow-up on most recent breast imaging (including mammography, MBI, MRI, ultrasound, etc.) not yet resolved prior to enrollment 2) Breast biopsy or breast surgery performed 6 months prior to enrollment 3) Bilateral breast implants or status post-bilateral prophylactic mastectomy 4) Pregnant or lactating 5) Current or recent use (within 6 months prior to enrollment) of any of the following drugs:
- •Systemic hormonal therapy (oral or transdermal patch formulations)
- •Hormonal contraception (oral, transdermal, implanted, or injected formulations)
- •Selective estrogen receptor modulators (tamoxifen, raloxifene, or toremifene)
- •Aromatase inhibitors (anastrazole, letrozole, or exemestane)
- •GnRH analogs
- •Prolactin inhibitors
- •Androgens or antiandrogens
- •Anticoagulants or "blood thinners" (warfarin, heparin, rivaroxaban and other novel anticoagulants)
- •Drugs known to be strong inhibitors of CYP2D6, the major P450 enzyme that metabolizes tamoxifen, including:
- •bupropion (Wellbutrin)
- •fluoxetine (Prozac)
- •paroxetine (Paxil)
- •quinidine (Quinidex) 6) Personal history of any type of malignancy, with the exclusion of non-melanoma skin cancer, diagnosed prior to enrollment 7) Personal history or strong family history of blood clots in legs or lungs (also known as deep vein thrombosis or pulmonary embolism) 8) Personal history of transient ischemic attack (TIA) or cerebrovascular accident (CVA) 9) Active proliferative disorders of the endometrium such as atypical hyperplasia, history of active endometriosis, unresected polyps 10) Any type of retinal disorders or severe cataract 11) Current or former smoker 12) Known carrier of BRCA1 or BRCA2 genetic mutation or known DNA repair defect.
研究组 & 干预措施
Tamoxifen 5 mg/day
Experimental
Women with high background uptake on MBI take 5 mg tam per day for 30 days.
干预措施: Tamoxifen (Drug)
Tamoxifen 10 mg/day
Experimental
Women with high background uptake on MBI take 10 mg tam per day for 30 days.
干预措施: Tamoxifen (Drug)
结局指标
主要结局
Change in Background Parenchymal Uptake (BPU) on Molecular Breast Imaging (MBI)
时间窗: 30 days
An image analysis tool to obtain a quantitative measure of background parenchymal uptake (BPU) was applied to pre-tamoxifen and post-tamoxifen MBI exams. The percent change in BPU from pre-tamoxifen to post-tamoxifen MBI was determined.
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
撤回
不适用
Prospective Analysis of Changes in Background Parenchymal Enhancement (BPE) and Amount of Fibroglandular Tissue on Breast MRIBreast CancerNCT01297231Memorial Sloan Kettering Cancer Center
已完成
不适用
The Ultrasound Study of TamoxifenBreast NeoplasmsNCT01582074National Cancer Institute (NCI)247
终止
2 期
Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia, Lobular Carcinoma In Situ, or Increased Breast Cancer RiskBreast Atypical HyperplasiaBreast Lobular Carcinoma in SituBreast Atypical Lobular HyperplasiaBreast CarcinomaNCT04570956Mayo Clinic65
Unknown
不适用
Tamoxifen Pharmacogenetics in Asian Breast Cancer WomenPoisoning by, Adverse Effect of and Underdosing of TamoxifenNCT01181518Inje University1,000
招募中
2 期
Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE TrialBreast CarcinomaNCT06184750National Cancer Institute (NCI)200